Ocular Therapeutix (OCUL) vs OPKO Health (OPK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
OPKO Health (OPK) has outperformed Ocular Therapeutix (OCUL) over the past year, gaining 18.9% versus a loss of 54.5%. Over five years, OCUL leads with a -14.8% price change compared with -62.0% for OPK. Ocular Therapeutix is the larger company by market cap ($1.23 billion vs $1.17 billion), about 1.1 times the size, while OPKO Health is growing revenue faster (-14.9% vs -18.5%).
OPKO Health converts more of its revenue into profit, with a net margin of -37.2% versus -511.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OCUL | OPK |
|---|---|---|
| Share price | $5.57 | $1.57 |
| Market cap | $1.23B | $1.17B |
| 1-day change | -4.95% | -2.48% |
| YTD return | -54.12% | +24.60% |
| 1-year return | -54.49% | +18.94% |
| 5-year return | -14.83% | -61.99% |
| EPS (TTM) | $-1.44 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $51.95M | $606.88M |
| Revenue growth (YoY) | -18.47% | -14.90% |
| Net income (latest FY) | $-265.94M | $-225.68M |
| Gross margin | 87.35% | 33.93% |
| Operating margin | -519.75% | -19.35% |
| Net margin | -511.90% | -37.19% |
| 52-week high | $16.44 | $1.86 |
| 52-week low | $5.54 | $0.98 |
| Distance from 52-week high | -66.12% | -15.59% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +361.94% | +164.33% |
| Average volume | 3.03M | 3.83M |
| Shares outstanding | 220.02M | 742.51M |
| Employees | 325 | 2,275 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OPK has outperformed OCUL by 73.4 percentage points over the past year.
- OPKO Health is more profitable, keeping -37.2 cents of every revenue dollar as net income versus -511.9 cents for Ocular Therapeutix.
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
About OPKO Health
OPK stock →OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,275 employees
OCUL vs OPK FAQ
Which is bigger, Ocular Therapeutix or OPKO Health?
Ocular Therapeutix (OCUL) is larger, with a market capitalization of $1.23B compared with $1.17B for OPKO Health (OPK).
Which stock has performed better over the past year, OCUL or OPK?
OPK returned +18.94% over the past 12 months, compared with -54.49% for OCUL (price return, excluding dividends). Past performance does not predict future results.
Are Ocular Therapeutix and OPKO Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.